- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT04350788
Enhancing Survivorship Care Planning for Patients With Localized Prostate Cancer Using A Couple-focused Web-based Tailored Symptom Self-management Program (SCP)
The purpose of this research study is to examine the feasibility of the enhanced survivorship care plans (ESCPs, regular SCPs with the a web-based couple-focused symptom self-management project (PERC) or National Cancer Institute prostate cancer web links) and to conduct an initial benefit assessment of enhanced survivorship care plans among prostate cancer patients transitioning from active treatment to post-treatment self-management, and their partners.
Participation of this study lasts for about for 16 weeks. Depending on participants' need for information, it takes 10-30 minutes of their time each week to review the information about prostate cancer.
Eligible and consented patients with newly treated localized prostate cancer and your partner (couples) are randomly assigned to the regular survivorship care plan (SCPs) with the NCI website or the enhanced survivorship care plans (SCP plus the web-based prostate cancer education program, PERC) groups. They complete baseline (T1, prior to randomization) and 4-month post-T1 follow-up measures (T2).
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
Methods: A two-group randomized controlled pretest-posttest design will be used and collect data at baseline (T1) and 4 months later (T2) among 50 patients completing initial treatment for localized prostate cancer and their partners. First, the investigators will assess the feasibility of ESCP by recruitment, enrollment, and retention rates, program satisfaction with the ESCP, and perceived ease of use of the ESCP. To achieve the secondary aim, the ESCP users will be compared with the standardized SCP users and assess their primary outcomes of QOL (overall, physical, emotional, and social QOL), secondary outcomes (reduction in negative appraisals and improvement in self-efficacy, social support, and health behaviors to manage symptoms), and number of visits to post-treatment care services at T1 and T2. The primary and secondary outcomes are assessed using measurements with sound psychometrical properties. The investigators will use a qualitative and quantitative mixed methods approach to achieve the research aims.
Conclusions: The results from this study will help design a definitive randomized trial to test the efficacy of the ESCPs, a potentially scalable program, to enhance supportive care for prostate cancer patients and their families.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
North Carolina
-
Chapel Hill, North Carolina, Stany Zjednoczone, 27559
- University of North Carolina at Chapel Hill
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
Eligibility included men who:
- were diagnosed with localized PC;
- were within 16 weeks of completing their initial curative intent treatment [26] at genitourinary and radiation oncology clinics at two comprehensive cancer centers in the U.S southeast;
- were not treated for another cancer in last year; and
- had a partner > 18 years of age not receiving cancer treatment.
Exclusion Criteria:
- Either member of couple unable to speak English
- Unwilling/unable to provide Informed Consent
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie podtrzymujące
- Przydział: Randomizowane
- Model interwencyjny: Przydział równoległy
- Maskowanie: Podwójnie
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Komparator placebo: Survivorship Care Plan (SCP)
The SCP group (control) participants were directed to the National Cancer Institute PC website (NCI) (http://www.cancer.gov/types/prostate),
|
Participants visit the NCI prostate cancer website in addition to their standardized post-treatment survivorship care
|
Eksperymentalny: Enhanced SCP (ESCP)
ESCP consists of the standard SCP that is enhanced by a couple-focused, tailored mHealth PC education program, the Patient Education Resources for Couples, to improve symptom management at home.
|
In addition to their standardized post-treatment survivorship care, participants visit the prostate cancer education resources for couples (PERC) website that was based on scientific evidence and input from stakeholders including PC patients, partners, and cancer care providers.
Participants learn about skills and knowledge about how to enhance their positive appraisals of symptoms and self-efficacy in symptom management through information and skills training, fostering healthy behaviors, and facilitating social support
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of Potentially Eligible Participants Actually Enrolled Into the Study
Ramy czasowe: after participants completed baseline survey
|
Will evaluate the percentage of patients and partners successfully consented and completing the baseline survey among all people approached for the study
|
after participants completed baseline survey
|
Percentage of Participants Enrolled Who Remained in the Study and Completed the Post-Intervention Follow-Up Survey
Ramy czasowe: during 4-month study period
|
Will evaluate the percentage of participants successfully following protocol, defined as completing the Follow-Up survey at the end of the study period among those who have been enrolled into the study (who completed the baseline).
|
during 4-month study period
|
Percentage of Participants That Used the Web-Based Intervention Sessions That Are Consistent With Patient-Reported Symptoms
Ramy czasowe: during 4-month study period
|
The usage of Web-Based Intervention Sessions is determined by the percentage of participants who logged into the study website among those who have been randomly assigned to the intervention group.
Patient-Reported Symptoms are determined by patient's responses on their appraisal of prostate cancer symptoms and general symptoms.
1=patient reported the symptom and the symptom webpage reviewed; 0=patient reported the symptom and no related webpage reviewed OR patient did not report the symptom but the webpage reviewed
|
during 4-month study period
|
Participant Satisfaction Scores
Ramy czasowe: at the 4 month followup
|
Program satisfaction determined by the 11-item Participant Satisfaction Scale measured the level of program satisfaction.
The first to tenth items ranged from 1=not satisfied to 5=extremely satisfied.
The eleventh item ranged from 1=extremely not to 4=definitely yes.
Higher total score indicates greater program satisfaction
|
at the 4 month followup
|
Perceived Ease of Use Score
Ramy czasowe: at the 4 month followup
|
The 16-item Program Usability measures participants' assessment of their agreement with the ease of use of the program in terms of its general features, content, and navigation.
The ranges of the total scores are (3,15), (4,20), (9,45) for general features, content, and navigation, respectively.
The score of individual item ranges from1=strongly disagree to 5=strongly agree.
Higher score indicates greater perceived ease of use.
|
at the 4 month followup
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change in FACT-G Scores
Ramy czasowe: Baseline upon enrollment, Month 4
|
Change in QOL determined using the Functional Assessment of Cancer Therapy General Scale (FACT-G) v.4, a 27-item measure yielding total score and scores for physical, social/family, emotional, and functional well-being of demonstrated reliability, validity, and sensitivity to change.
FACT-G consists of 4 subscales: physical well-being (PWB), functional well-being (FWB), emotional well-being (EWB) and social well-being (SWB).
Scores on the four subscales are summed to produce a total score ranging from 0 to 108 with higher scores indicating better quality of life.
Change from baseline is the post-Baseline values minus the Baseline value.
|
Baseline upon enrollment, Month 4
|
Change in Appraisal of Prostate Cancer-Specific Symptoms
Ramy czasowe: Baseline upon enrollment, Month 4
|
The Expanded Prostate Cancer Index Composite (EPIC) is a comprehensive instrument designed to evaluate patient function and bother after prostate cancer treatment.
EPIC will be used to measure change in appraisal of symptoms scores among patients from Baseline (T1) to T2 (4 months post T1).
EPIC contains 26 items within 5 domains: Urinary Incontinence, Urinary Irritative/Obstructive, Bowel, Sexual, and Hormonal.
Response options for each EPIC item form a Likert scale, and multi-item scale scores are transformed linearly to a 0-100 scale, with higher scores representing opposite results by role: patient with better appraisal of symptoms and partner with worse appraisal of symptoms.
Change from baseline is the post-Baseline values minus the Baseline value.
|
Baseline upon enrollment, Month 4
|
Change in Appraisal of General Symptoms
Ramy czasowe: Baseline upon enrollment, Month 4
|
The 19-item Risk for Distress-general symptoms is a subscale of the Risk for Distress Scale.
It measures how much trouble the participant has with the general symptoms such as pain, fatigue, and etc.
The total score ranges between 0 and 38, with higher scores indicating worse appraisal of symptoms.
Change from baseline is the post-Baseline values minus the Baseline value.
|
Baseline upon enrollment, Month 4
|
Healthcare Utilization Extracted From Electronic Medical Record
Ramy czasowe: during the first 10 months after participants completed baseline survey
|
The total number of prostate cancer-related followup visits, emergency room use and readmissions.
|
during the first 10 months after participants completed baseline survey
|
Change in Self-Efficacy Scores From Baseline to 4-Months Post Baseline
Ramy czasowe: Baseline upon enrollment, Month 4
|
The Lewis Cancer Self-Efficacy used to measure change in participants' feelings of self-efficacy in dealing with the patient's cancer diagnosis and treatment from Baseline (T1) to T2 (4 months post T1).
Participants rate statements about how confident they feel on a scale from 1 to 10, where higher scores indicate higher self-efficacy.
|
Baseline upon enrollment, Month 4
|
Change in PROMIS Social Support-Informational Support From Baseline to 4-Months Post-Baseline
Ramy czasowe: Baseline upon enrollment, Month 4
|
The Patient-Reported Outcomes Measurement Information System (PROMIS) Informational Support Short Form 8a will be used to assess changes in patient and partner reported informational support system using a 5-point Likert scale from Baseline (T1) to T2 (4 months post T1).
The total score range: 8-40.
Higher scores indicate more informational support.
Change from baseline is the post-Baseline values minus the Baseline value.
|
Baseline upon enrollment, Month 4
|
Change in PROMIS Social Support-Emotional Support From Baseline to 4-months Post-Baseline
Ramy czasowe: Baseline upon enrollment, Month 4
|
The PROMIS Emotional Support System-Short Form 8a will be used to assess changes in the self-reported emotional support system of patients and their partners using a 5-point Likert scale from Baseline (T1) to T2 (4 months post T1).
The total score range: 8-40.
Higher scores indicate more emotional social support.
Change from baseline is the post-Baseline values minus the Baseline value.
|
Baseline upon enrollment, Month 4
|
Change in PROMIS Social Support-Instrumental Support From Baseline to 4-months Post-Baseline
Ramy czasowe: Baseline upon enrollment, Month 4
|
The PROMIS Instrumental Support-Short Form 8a will be used to assess changes in patient and partner reported instrumental support system using a 5-point Likert scale from Baseline (T1) to T2 (4 months post T1).
The total score range: 8-40.
Higher scores indicate more instrumental support.
Change from baseline is the post-Baseline values minus the Baseline value.
|
Baseline upon enrollment, Month 4
|
Change in Dietary Risk Assessment Scores From Baseline to 4-month Post Baseline as Measured by the Health Promoting Lifestyle Profile II
Ramy czasowe: Baseline upon enrollment, Month 4
|
Change in Dietary Risk Assessment scores used to measure changes in dietary risk from Baseline (T1) to T2 (4 months post T1).
Change from baseline is the post-Baseline values minus the Baseline value.
Participants are asked how often they consume different foods over the past month or week and respond using a Likert Scale ranging from 1=never to 4=routinely.
The total score range: 8-32.
Higher scores indicate better health behaviors in nutrition.
|
Baseline upon enrollment, Month 4
|
Change in Physical Activity Assessment Scores From Baseline to 4-month Post Baseline as Measured by the Health Promoting Lifestyle Profile II
Ramy czasowe: Baseline upon enrollment, Month 4
|
Change in Physical Activity Assessment scores used to measure changes in physical activity from Baseline (T1) to T2 (4 months post T1).
Change from baseline is the post-Baseline values minus the Baseline value.
Participants are asked how often they engage in exercises and physical activity over the past month or week and respond using a Likert Scale, ranging from 1=never to 4=routinely.
The total score range: 9-36.
Higher scores indicate better health behaviors in physical activity.
|
Baseline upon enrollment, Month 4
|
Współpracownicy i badacze
Współpracownicy
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- LCCC 1619
- 1R21CA212516 (Grant/umowa NIH USA)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Ramy czasowe udostępniania IPD
Kryteria dostępu do udostępniania IPD
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Rak prostaty
-
Emory UniversityNational Cancer Institute (NCI)WycofanePrognostyczny rak piersi IV stopnia AJCC v8 | Przerzutowy nowotwór złośliwy w mózgu | Przerzutowy rak piersi | Anatomiczny IV stopień raka piersi American Joint Committee on Cancer (AJCC) v8
-
Jonsson Comprehensive Cancer CenterZakończonyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterZakończonyBiochemicznie nawracający rak prostaty | Przerzutowy rak prostaty | Nowotwór złośliwy z przerzutami w kości | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterEli Lilly and Company; Genentech, Inc.RekrutacyjnyNiedrobnokomórkowy rak płuc z przerzutami | Oporny na leczenie niedrobnokomórkowy rak płuc | Rak płuca w stadium IV American Joint Committee on Cancer (AJCC) v8 | Rak płuc w stadium IVA AJCC v8 | Rak płuc w stadium IVB AJCC v8Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)ZakończonyGruczolakorak gruczołu krokowego III stopnia AJCC v7 | Gruczolakorak gruczołu krokowego II stopnia AJCC v7 | Stopień I gruczolakoraka gruczołu krokowego American Joint Committee on Cancer (AJCC) v7Stany Zjednoczone
-
Jonsson Comprehensive Cancer CenterRekrutacyjnyRak prostaty oporny na kastrację | Przerzutowy rak prostaty | Stadium IVA raka prostaty AJCC v8 | Rak prostaty w stadium IVB AJCC v8 | Rak prostaty w stadium IV American Joint Committee on Cancer (AJCC) v8Stany Zjednoczone
-
NRG OncologyNational Cancer Institute (NCI)Aktywny, nie rekrutującyAnatomiczny rak piersi IV stadium AJCC v8 | Prognostyczny rak piersi IV stopnia AJCC v8 | Nowotwór złośliwy z przerzutami w kości | Przerzutowy nowotwór złośliwy w węzłach chłonnych | Przerzutowy nowotwór złośliwy w wątrobie | Przerzutowy rak piersi | Przerzutowy nowotwór złośliwy w płucach | Nowotwór... i inne warunkiStany Zjednoczone, Kanada, Arabia Saudyjska, Republika Korei
-
National Cancer Institute (NCI)ZakończonyOporny na leczenie złośliwy nowotwór lity | Nawracający złośliwy nowotwór lity | Przerzutowy złośliwy nowotwór lity | Nieoperacyjny lity nowotwór | Nawracający rak drobnokomórkowy płuca | Stopień IIIA Rak drobnokomórkowy płuca AJCC v7 | Etap IIIB Rak drobnokomórkowy płuca AJCC v7 | Rak drobnokomórkowy... i inne warunkiStany Zjednoczone
-
Jonsson Comprehensive Cancer CenterBeiGene; Driven To CureWycofanePrzerzutowy rak nerkowokomórkowy | Rak nerkowokomórkowy IV stopnia AJCC v8 | Rak brodawkowaty nerki | Zbieranie raka przewodów | Nieoperacyjny rak nerki | Dziedziczna leiomyomatoza i rak nerkowokomórkowy | Jasnokomórkowy brodawkowaty nowotwór nerki | Dziedziczny rak brodawkowaty nerki | Niesklasyfikowany... i inne warunkiStany Zjednoczone
-
Jonsson Comprehensive Cancer CenterAstraZenecaZakończonyRak płaskonabłonkowy jamy ustnej i gardła | Stopień kliniczny III zależny od HPV (p16-dodatni) rak jamy ustnej i gardła AJCC v8 | Stopień kliniczny II, w którym pośredniczy HPV (p16-dodatni) rak jamy ustnej i gardła AJCC v8 | Patologiczny etap I, w którym pośredniczy HPV (p16-dodatni) rak jamy... i inne warunkiStany Zjednoczone
Badania kliniczne na Survivorship Care Plan
-
Baylor College of MedicineThe University of Texas Health Science Center, Houston; University of Texas... i inni współpracownicyRekrutacyjnyJakość życia | Objawy depresyjne | Nowotwór jajnikaStany Zjednoczone
-
Wake Forest University Health SciencesZakończonyNieokreślony guz lity wieku dziecięcego, specyficzny dla protokołu | Rzekomy śluzak otrzewnej | Rak nabłonkowy jajnika w stadium IV | Guz zarodkowy jajnika w stadium IV | Mięsak jajnika | Nawracający rak nabłonka jajnika | Rak okrężnicy w stadium IV | Nawracający rak jelita grubego | Rak dodatku | Rak stromalny... i inne warunkiStany Zjednoczone
-
University College CorkSidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Cork University... i inni współpracownicyAktywny, nie rekrutującyRak szyjki macicy | Rak piersi | Rak endometrium | PrzetrwanieIrlandia
-
University of California, San FranciscoWashington University School of Medicine; University of Washington; Pacific Pediatric... i inni współpracownicyRekrutacyjnyRdzeniak zarodkowy | Medulloblastoma, dzieciństwo | Nawracający rdzeniak zarodkowyStany Zjednoczone
-
University of CopenhagenUniversity of Parma; Fundació Eurecat; ONMI; Simple Feast; AlimentómicaZakończonyOtyłość | Nadwaga | Syndrom metablicznyDania
-
Silke Wiegand-Grefe, Prof. Dr.Charite University, Berlin, Germany; Hannover Medical School; University Hospital... i inni współpracownicyAktywny, nie rekrutujący
-
University Hospital, LilleMinistry of Health, FranceNieznany
-
Riphah International UniversityZakończonyPorażenie mózgowePakistan
-
Wake Forest University Health SciencesNational Institute on Aging (NIA); Health Resources and Services Administration...RekrutacyjnyHIV | Starzenie sięStany Zjednoczone